%0 Journal Article %1 Lange.2011 %A Lange, T. %A Hubmann, M. %A Burkhardt, R. %A Franke, G-N %A Cross, M. %A Scholz, Markus %A Leiblein, S. %A Al-Ali, H. K. %A Edelmann, J. %A Thiery, J. %A Niederwieser, D. %D 2011 %J Leukemia %K IMISE-Publikationen %N 3 %P 498–505 %T Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning %V 25 %X Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), donor chimerism (DC) analysis of unsorted (UDC) or CD34(+) sorted cells and Wilms' tumor gene 1 (WT1) expression. Eighty-eight patients with AML or MDS were monitored after allogenic HCT following 2 Gy total-body irradiation with (n=84) or without (n=4) fludarabine 3 × 30 mg/m(2), followed by cyclosporin A and mycophenolate mofetil. DSMs were determined by fluorescence in situ hybridization (FISH) and WT1 expression by real-time polymerase chain reaction. Chimerism analysis was performed on unsorted or CD34(+) sorted cells, by FISH or short tandem repeat polymerase chain reaction. Twenty-one (24\%) patients relapsed within 4 months after HCT. UDC, CD34(+) DC and WT1 expression were each significant predictors of relapse with sensitivities ranging from 53 to 79\% and specificities of 82-91\%. Relapse within 28 days was excluded almost entirely on the basis of WT1 expression combined with CD34(+) DC kinetics. Monitoring of WT1 expression and CD34(+) DC predict relapse of AML and MDS after RIC-HCT.

@article{Lange.2011, abstract = {Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), donor chimerism (DC) analysis of unsorted (UDC) or CD34(+) sorted cells and Wilms' tumor gene 1 (WT1) expression. Eighty-eight patients with AML or MDS were monitored after allogenic HCT following 2 Gy total-body irradiation with (n=84) or without (n=4) fludarabine 3 × 30 mg/m(2), followed by cyclosporin A and mycophenolate mofetil. DSMs were determined by fluorescence in situ hybridization (FISH) and WT1 expression by real-time polymerase chain reaction. Chimerism analysis was performed on unsorted or CD34(+) sorted cells, by FISH or short tandem repeat polymerase chain reaction. Twenty-one (24\%) patients relapsed within 4 months after HCT. UDC, CD34(+) DC and WT1 expression were each significant predictors of relapse with sensitivities ranging from 53 to 79\% and specificities of 82-91\%. Relapse within 28 days was excluded almost entirely on the basis of WT1 expression combined with CD34(+) DC kinetics. Monitoring of WT1 expression and CD34(+) DC predict relapse of AML and MDS after RIC-HCT.}, added-at = {2014-10-14T15:28:05.000+0200}, author = {Lange, T. and Hubmann, M. and Burkhardt, R. and Franke, G-N and Cross, M. and Scholz, Markus and Leiblein, S. and Al-Ali, H. K. and Edelmann, J. and Thiery, J. and Niederwieser, D.}, biburl = {https://www.bibsonomy.org/bibtex/27c7cee93434a626579283a67b675b258/drtester}, interhash = {2fb36fa8f144e06624a3beda7d09d51d}, intrahash = {7c7cee93434a626579283a67b675b258}, journal = {Leukemia}, keywords = {IMISE-Publikationen}, number = 3, pages = {498–505}, timestamp = {2014-12-03T00:08:47.000+0100}, title = {Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning}, volume = 25, year = 2011 }